Asensus Surgical, Inc. (NYSEAMERICAN:ASXC) Short Interest Update

Asensus Surgical, Inc. (NYSEAMERICAN:ASXC – Get Rating) was the target of a large decrease in short interest in February. As of February 15th, there was short interest totalling 9,950,000 shares, a decrease of 9.5% from the January 31st total of 10,990,000 shares. Based on an average trading volume of 1,640,000 shares, the short-interest ratio is presently 6.1 days. Approximately 4.3% of the shares of the company are short sold.

Asensus Surgical Stock Performance

Shares of Asensus Surgical stock opened at $0.73 on Friday. The company has a fifty day moving average price of $0.54. Asensus Surgical has a fifty-two week low of $0.28 and a fifty-two week high of $1.18. The firm has a market capitalization of $172.89 million, a price-to-earnings ratio of -2.28 and a beta of 1.81.

Institutional Investors Weigh In On Asensus Surgical

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. lifted its position in shares of Asensus Surgical by 5.3% during the 3rd quarter. Vanguard Group Inc. now owns 11,431,792 shares of the company’s stock valued at $5,130,000 after acquiring an additional 575,904 shares during the last quarter. Millennium Management LLC lifted its holdings in shares of Asensus Surgical by 3,552.4% during the second quarter. Millennium Management LLC now owns 5,040,838 shares of the company’s stock valued at $2,007,000 after purchasing an additional 4,902,823 shares during the last quarter. UBS Group AG lifted its holdings in shares of Asensus Surgical by 74.0% during the fourth quarter. UBS Group AG now owns 565,658 shares of the company’s stock valued at $198,000 after purchasing an additional 240,648 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in Asensus Surgical by 41.2% in the 3rd quarter. Price T Rowe Associates Inc. MD now owns 296,100 shares of the company’s stock worth $134,000 after purchasing an additional 86,400 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in Asensus Surgical by 68.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 210,737 shares of the company’s stock worth $133,000 after purchasing an additional 85,487 shares in the last quarter. 11.96% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $3.00 target price on shares of Asensus Surgical in a report on Wednesday, February 22nd.

About Asensus Surgical

(Get Rating)

Asensus Surgical, Inc is a medical device company, which digitizes the interface between the surgeon and the patient to improve minimally invasive surgery through digital laparoscopy. It enables the use of advanced capabilities like augmented intelligence, connectivity and robotics in laparoscopy, and addresses the current clinical, cognitive, and economic shortcomings in surgery.